MAD4 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB100-1117
Key Product Details
Species Reactivity
Human
Applications
Peptide ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence GPHCRRLGRPALS corresponding to C-Terminus according to NP_006445.1.
Localization
Nuclear
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for MAD4 Antibody
Western Blot: MAD4 Antibody [NB100-1117]
Western Blot: MAD4 Antibody [NB100-1117] - (0.5 ug/ml) of human kidney lysate (RIPA buffer, 35 ug total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescenceApplications for MAD4 Antibody
Application
Recommended Usage
Peptide ELISA
Detection limit 1:16000
Western Blot
0.5 - 2 ug/ml
Application Notes
WB: Approx. 22 kDa band observed in human kidney lysates (predicted MW of 24 kDa band according to NP_006445). Please note the appearance of this band was blocked by incubation with the immunizing peptide.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: MAD4
Alternate Names
BHLHC12, bHLHc12Max-interacting transcriptional repressor MAD4, Class C basic helix-loop-helix protein 12, Mad4 homolog, MAD4Max-associated protein 4, MAX dimerization protein 4, Max dimerizer 4, MST149, MSTP149, MXD4 MAX dimerization protein 4
Entrez Gene IDs
10608 (Human)
Gene Symbol
MXD4
UniProt
Additional MAD4 Products
Product Documents for MAD4 Antibody
Product Specific Notices for MAD4 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...